News

The Portal study is a long-term extension of the phase 3 Archway study

Genentech reveals five-year data showing Susvimo effectively maintains vision in wet AMD patients with fewer injections, offering a promising treatment alternative.

TearCare is associated with greater health utility over time but also resulted in significant cost savings compared with CsA

4D-150 is an investigational agent designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.

The solution was approved by the US Food and Drug Administration in late May 2025.

RTP-008 features sustained immunosuppressant delivery for long-term therapeutic effects.

Clearside Biomedical secures Health Canada approval for Xipere, while exploring strategic options to enhance its suprachoroidal delivery platform and pipeline.

Justis Ehlers, MD, FASRS, presented "PER-001, a Long-acting Endothelin Antagonist Intravitreal Implant, Improved Structure and Visual Function in Patients With Diabetic Retinopathy," during the 2025 ASRS meeting held in Long Beach, California.

Steven D. Ness, MD, discusses his research on vitamin D's role in reducing complications after retinal surgery at ASRS 2025.

Catch up on this week's highlights in retina.

At ASRS 2025, Andrew G Lee, MD, gave key insight into the world of a neuro-ophthalmologist and why and when a retina specialist should consult a neuro-ophthalmologist

Christina Weng, MD, MBA, FASRS, explores the viability of postoperative day 0 exams as a substitute for day 1 after vitreoretinal surgery, revealing promising findings.

Optomed Lumo launches a versatile handheld fundus camera, enhancing retinal imaging accessibility in diverse healthcare settings across the US.

Andrew G. Lee, MD, shares essential insights on neuro-ophthalmology for retina specialists, emphasizing diagnosis techniques and collaboration with neuro-ops.

The Global RDH12 Alliance unites inherited retinal disease advocacy groups including UK-based Eyes on the Future and the US-based RDH12 Fund for Sight

Dilsher S. Dhoot, MD, FASRS, shares insights on avoralstat, a promising treatment for diabetic macular edema, at ASRS 2025.

Vizz (Lenz Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution to correct vision for up to 10 hours.

Yasha S. Modi, MD, discusses promising results from the VERONA study on EYP-1901, a potential treatment for diabetic macular edema.

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.